R
Rocio Garcia-Carbonero
Researcher at Complutense University of Madrid
Publications - 221
Citations - 5763
Rocio Garcia-Carbonero is an academic researcher from Complutense University of Madrid. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 29, co-authored 172 publications receiving 3426 citations. Previous affiliations of Rocio Garcia-Carbonero include Charité & Ministry of Science and Innovation.
Papers
More filters
Journal ArticleDOI
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Thierry André,Kai-Keen Shiu,Tae Won Kim,Benny Vittrup Jensen,Lars Henrik Jensen,Cornelis J. A. Punt,Denis Smith,Rocio Garcia-Carbonero,Manuel Benavides,Peter Gibbs,Christelle De La Fouchardiere,Fernando Rivera,Elena Elez,Johanna C. Bendell,Dung T. Le,Takayuki Yoshino,Eric Van Cutsem,Ping Yang,Mohammed Z.H. Farooqui,Patricia Marinello,Luis A. Diaz,Keynote Investigators +21 more
TL;DR: Pembrolizumab led to significantly longer progression-free survival than chemotherapy when received as first-line therapy for MSI-H-dMMR metastatic colorectal cancer, with fewer treatment-related adverse events.
Journal ArticleDOI
ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas
Rocio Garcia-Carbonero,Halfdan Sorbye,Eric Baudin,Eric Raymond,Bertram Wiedenmann,Bruno Niederle,Eva Sedlackova,Christos Toumpanakis,Martin Anlauf,Jarosław B. Ćwikła,Martyn Caplin,Dermot O'Toole,Aurel Perren +12 more
TL;DR: a Medical Oncology Department, Hospital Universitario Doce de Octubre, Madrid , Spain; b Department of oncology, Haukeland University Hospital, Bergen , Norway; c Institut Gustave Roussy, Villejuif, and d Oncologie Médicale, Hôpitaux Universitaires Paris Nord Val de Seine, Paris , France.
Journal ArticleDOI
Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer.
Davide Melisi,Rocio Garcia-Carbonero,Teresa Macarulla,Denis Pezet,Gael Deplanque,M. Fuchs,Jörg Trojan,Helmut Oettle,Mark Kozloff,Ann Cleverly,Claire Smith,Shawn T. Estrem,Ivelina Gueorguieva,Michael Lahn,Al Blunt,Karim A. Benhadji,Josep Tabernero +16 more
TL;DR: Lower baseline biomarkers macrophage inflammatory protein-1-alpha and interferon-gamma-induced protein 10 were associated with galunisertib benefit, and future exploration of galun isertib in pancreatic cancer is ongoing in combination with durvalumab.
Journal ArticleDOI
Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia : a multicenter randomized trial
Rocio Garcia-Carbonero,Jose I. Mayordomo,María Victoria Tornamira,Marta López-Brea,Antonio Rueda,Vicente Guillem,Alberto Arcediano,A. Yubero,Fernando Ribera,Carlos Lage Gómez,Alejandro Tres,Jose Luis Perez-Gracia,Carlos Lumbreras,Javier Hornedo,Hernán Cortés-Funes,Luis Paz-Ares +15 more
TL;DR: Adding G-CSF to antibiotic therapy shortens the duration of neutropenia, reduces the durationOf antibiotic therapy and hospitalization, and decreases hospital costs in patients with high-risk febrile neutropensia is evaluated.
Journal ArticleDOI
Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 Study.
Thierry André,Kai-Keen Shiu,Tae Won Kim,Benny Vittrup Jensen,Lars Henrik Jensen,Cornelis J. A. Punt,Denis Smith,Rocio Garcia-Carbonero,Manuel Benavides,Peter Gibbs,Christelle De La Fouchardiere,Fernando Rivera,Elena Elez,Johanna C. Bendell,Dung T. Le,Takayuki Yoshino,Ping Yang,Mohammed Z.H. Farooqui,Patricia Marinello,Luis A. Diaz +19 more
TL;DR: LBA4 is a phase 3, randomized open-label study evaluating the efficacy and safety of pembrolizumab (pembro) versus standard of care chemotherapy ± bevacIZumab o...